Peripheral arterial disease and Virchow's triad

Thrombosis and Haemostasis

Volumn 101, Issue 6, 2009, Pages 1032-1040

  Bennett, Philip C ^a   Silverman, Stanley H ^a   Gill, Paramjit S ^b   Lip, Gregory Y H ^a  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Arterial thrombosis; Clinical studies; Risk factors

Indexed keywords

BETA THROMBOGLOBULIN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHOLESTEROL; CYTOKINE; D DIMER; FIBRINOGEN; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THROMBOMODULIN; THROMBOPLASTIN; THROMBOSPONDIN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER; PLASMA PROTEIN;

ARTERY BLOOD FLOW; ARTERY COMPLIANCE; ARTERY THROMBOSIS; ARTERY WALL; ATHEROGENESIS; BLOOD FLOW VELOCITY; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DOPPLER FLOWMETRY; DYSLIPIDEMIA; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; GANGRENE; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; INFLAMMATION; INTERMITTENT CLAUDICATION; LEG PAIN; LEG ULCER; OBESITY; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SHEAR STRESS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS; BLOOD; BLOOD CLOTTING; BLOOD FLOW; BLOOD VESSEL; CLASSIFICATION; IMMUNOLOGY; METABOLISM; PATHOLOGY; PERIPHERAL VASCULAR DISEASES; SEVERITY OF ILLNESS INDEX; STENOSIS, OCCLUSION AND OBSTRUCTION; THROMBOCYTE; VASCULAR ENDOTHELIUM;

BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD PLATELETS; BLOOD PROTEINS; BLOOD VESSELS; CONSTRICTION, PATHOLOGIC; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; INTERMITTENT CLAUDICATION; PERIPHERAL VASCULAR DISEASES; PROGNOSIS; REGIONAL BLOOD FLOW; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 67049158040     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-08-0518     Document Type: Review

References (163)

1. Hirsch AT, Haskal ZJ. ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) Circulation 2006; 113: e463-e465.
2. Norgren L, et al. on behalf of the TASC II working group. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33: S1-S75.
3. Criqui MH, et al. Mortality over a period of 10years in patients with peripheral arterial disease. New Engl J Med 1992; 326: 381-386.
4. Criqui MH, Denenberg JO. The generalised nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med 1998; 3: 241-245. (Pubitemid 28553010)
5. Dormandy J, et al. Lower extremity arteriosclerosis as a reflection of a systemic process: implications for concomitant coronary and carotid disease. Semin Vasc Surg 1999; 12: 118-122. (Pubitemid 29259199)
6. Virchow RLK. Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Frankfurt, Meidinger Sohn & Co., 1856. In, Virchow RLK. Thrombosis and Emboli (1846-1856). Matzdorff AC, Bell WR (transl). Canton, Science History Publications, 1998; 5-11, 110.
7. Makin AJ, et al. Peripheral vascular disease and Virchow's triad for thrombogenesis. Q J Med 2002; 95: 199-210. (Pubitemid 34413726)
8. Chung I, Lip GYH. Virchow's triad revisited: Blood constituents. Pathophysiol Haemost Thromb 2003/2004; 33: 449-454. (Pubitemid 40278723)
9. Lowe GDO. Virchow's triad revisited: Abnormal Flow. Pathophysiol Haemost Thromb 2003/2004; 33: 455-457. (Pubitemid 40278724)
10. Lip GY, Blann AD. Thrombogenesis, atherogenesis and angiogenesis in vascular disease: a new 'vascular triad'. Ann Med 2004; 36: 119-125.
11. Ross R. Atherosclerosis- An inflammatory disease. New Engl J Med 1999; 340: 115-126. (Pubitemid 29054847)
12. Stary HC, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1512-1531.
13. Ridker PM. Fibrinolytic and inflammatory markers for arterial occlusion: the evolving epidemiology of thrombosis and haemostasis. Thromb Haemost 1997; 78: 53-59. (Pubitemid 27289215)
14. Hiatt WR. Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy. J Intern Med 2002; 251: 193-206. (Pubitemid 34227183)
15. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844. (Pubitemid 30943820)
16. Brevetti G, et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg 2003; 38: 374-379. (Pubitemid 41123265)
17. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999; 34: 631-638. (Pubitemid 29436165)
18. Corretti MC, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow mediated vasodilation of the brachial artery. J Am Coll Cardiol 2002; 39: 257-265.
19. Bonetti PO, et al. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-175. (Pubitemid 36231924)
20. Lip GY, Blann. Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34: 255-265.
21. Zanetta L, et al. Expression of Von Willebrand factor, an endothelial cell marker, is up-regulated by angiogenesis factors: a potential method for objective assessment of tumour angiogenesis. Int J Cancer 2000; 85: 281-288. (Pubitemid 30023080)
22. Blann AD, et al. Von Willebrand factor, the endothelium and obesity. Int J Obes Relat Metab Disord 1993; 17: 723-725. (Pubitemid 24006348)
23. Blann AD, et al. Von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 1993; 7: 107-111. (Pubitemid 23138184)
24. Spencer CG, et al. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension; a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension 2002; 40: 61-66. (Pubitemid 34755980)
25. Ruggeri ZM. Perspectives series: cell adhesion in vascular biology. Von Willebrand Factor. J Clin Invest 1997; 99: 559-564.
26. Blann AD, et al. Relationship between endothelial cell markers and arterial stenosis in peripheral and carotid artery disease. Thromb Res 2000; 97: 209-216. (Pubitemid 30069709)
27. Seigneur M, et al. Circulating endothelial markers and ischaemic status in peripheral occlusive arterial disease. Nouv Rev Fr Haematol 1995; 37: 171-173.
28. Lee AJ, et al. Determinants of fibrin d-dimer in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1995; 15: 1094-1097.
29. Cassar K, et al. Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. Eur J Endovasc Surg 2005; 29: 171-176. (Pubitemid 40104007)
30. Cassar K, et al. Platelet activation is increased in peripheral arterial disease. J Vasc Surg 2003; 38: 99-103. (Pubitemid 41123295)
31. Woodburn KR, et al. Fibrinogen and markers of fibrinolysis and endothelial damage following resolution of critical limb ischaemia. Eur J Vasc Endovasc Surg 1995; 10: 272-278.
32. Peterson J, et al. Expression of thrombomodulin and consequences of thrombomodulin deficiency during healing of cutaneous wounds. Am J Pathol 1999; 155: 1569-1575.
33. Ishii H, et al. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65: 618-623.
34. Boffa MC, et al. Plasma thrombomodulin as a marker of endothelial damage. Nouv Rev Fr Hematol 1991; 33: 529-530.
35. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995; 9: 946-955.
36. Blann AD, et al. Circulating endothelial cell markers in peripheral vascular disease: Relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest 1997; 27: 916-921. (Pubitemid 27483525)
37. Constans J, et al. Endothelial function, platelet activation and coagulation in lower limb occlusive arterial disease during treadmill exercise: correlations with transcutaneous oxygen pressure. Thromb Res 2000; 99: 557-561. (Pubitemid 30642735)
38. Taskiris DA, et al. Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis 1999; 142: 193-200. (Pubitemid 28551825)
39. Salomaa V, et al. Cross-sectional association of soluble thrombomodulin with mild peripheral arterial disease: the ARIC study. Atherosclerosis Risk in Communities. Atherosclerosis 2001; 157: 309-314. (Pubitemid 32710009)
40. Sernau T, et al. Thrombomodulin is a marker of microvascular, but not for macrovascular endothelial cell damage. Vasa 1995; 24: 347-353.
41. Peter K, et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 1997; 17: 505-512. (Pubitemid 27133140)
42. Blann AD, et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005; 93: 228-235.
43. Lee KW, et al. Inter-relationships of indices of endothelial damage/ dysfunction [circulating endothelial cells, von Willebrand factor and flow-mediated dilatation] to tissue factor and interleukin-6 in acute coronary syndromes Int J Cardiol 2006; 111: 302-308.
44. Strijbos MH, et al. Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage. Thromb Haemost 2008; 100: 642-647.
45. Rajagopalan S, et al. Endothelial cell apoptosis in systemic lupus erythematosis: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004; 103: 3677-3683. (Pubitemid 38596281)
46. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001; 88: 756-762. (Pubitemid 32429970)
47. Freedman JE, et al. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 1998; 98: 1481-1486. (Pubitemid 28481663)
48. Makin AJ, et al. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Eur Heart J 2004; 25: 371-376.
49. Makin AJ, et al. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clinical Science 2003; 104: 397-404.
50. Blann AD, et al. Differences in free and total tissue factor pathway inhibitor, and tissue factor in peripheral artery disease compared to healthy controls. Atherosclerosis 2000; 152: 29-34.
51. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clinica Chimica Acta 2006; 368: 33-47. (Pubitemid 43792418)
52. Davies MJ, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-Selectin in human atherosclerosis. J Path 1993; 171: 223-229. (Pubitemid 23345967)
53. Khalegi M, et al. Association of soluble cell adhesion molecules with ankle-brachial index in a biethnic cohort of predominantly hypertensive individuals. Clin Chem 2008; 54: 1788-1795.
54. Iwashima Y, et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis 2006; 188: 384-390. (Pubitemid 44301128)
55. Pradhan AD, et al. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002; 106: 820-825.
56. Tzoulaki I, et al. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J 2007; 28: 354-362. (Pubitemid 46254637)
57. Silvestro A, et al. Adhesion molecules and cardiovascular risk in peripheral arterial disease. Soluble vascular cell adhesion molecule-1 improves risk stratification. Thromb Haemost 2005; 93: 559-563.
58. Lee WL, et al. The short-/intermediate-term changes in novel vascular inflammatory markers after angioplasty plus stenting in patents with symptomatic advanced systemic arterial diseases. Atherosclerosis 2004; 176: 125-132. (Pubitemid 39078654)
59. Allan PL, et al. Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease. The Edinburgh Artery Study. Stroke 1997; 28: 348-353. (Pubitemid 27097003)
60. O'Leary DH, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
61. Markus H, et al. Increased common carotid intimamedia thickness in UK African Caribbeans and its relation to chronic inflammation and vascular candidate gene polymorphisms. Stroke 2001; 32: 2465-2471. (Pubitemid 33055290)
62. Mohan V, et al. Intimal medial thickness of the carotid artery in South Indian diabetic and non-diabetic subjects: the Chennai Urban Population Study (CUPS). Diabetologia 2000; 43: 494-499. (Pubitemid 30237959)
63. Baldassarre D, et al. Carotid intima-media thickness and markers of inflammation, endothelial damage and hemostasis. Ann Med 2008; 40: 21-44. (Pubitemid 351197923)
64. Baldassarre D, et al. Measurement of carotid artery intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events. Atherosclerosis 2007; 191: 403-408.. (Pubitemid 46400703)
65. Bernard S, et al. Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic type 2 diabetic subjects. Diabetes Care 2005; 28: 1158-1162. (Pubitemid 40616628)
66. McDermott MM, et al. Ankle-Brachial Index and subclinical cardiac and carotid disease. The Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 2005; 162: 33-41. (Pubitemid 40884998)
67. Price JF, et al. Ankle brachial index and intima media thickness predict cardiovascular events similarly and increased prediction when combined. J Clin Epidemiol 2007; 60: 1067-1075. (Pubitemid 47404817)
68. Laurent S, et al. on behalf of the European Network for Non-invasive investigation of larger arteries. Eur Heart J 2006; 27: 2588-2605.
69. Chobnanian AV. Isolated systolic hypertension in the elderly. N Eng J Med 2007; 357: 789-796. (Pubitemid 47295645)
70. Avolio AP, et al. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China. Circulation 1985; 71: 202-210. (Pubitemid 15157079)
71. Laurent S, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-1241. (Pubitemid 34163575)
72. Meaume S, et al. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol 2001; 21: 2046-2050. (Pubitemid 34219760)
73. Kals J, et al. Impact of oxidative stress on arterial elasticity in patients with atherosclerosis. Am J Hypertens 2006; 19: 902-908. (Pubitemid 46106988)
74. Tai NR, et al. In vivo femoropopliteal arterial wall compliance in subjects with and without lower limb vascular disease. J Vasc Surg 1999; 30: 936-945.
75. McVeigh GE, et al. Vascular abnormalities associated with long term cigarette smoking identified by arterial waveform analysis. Am J Med 1997; 102: 227-231. (Pubitemid 27202830)
76. Seals DR, et al. Habitual exercise and arterial aging. J Appl Physiol 2008; 105: 1323-1332.
77. Khaleghi M, Kullo IJ. Aortic augmentation index is associated with the ankle brachial pressure index: A community-based study. Atherosclerosis 2007; 195: 248-253. (Pubitemid 350087952)
78. Brewer LC, et al. Measures of arterial stiffness and wave reflection are associated with walking distance in patients with peripheral arterial disease. Atherosclerosis 2007; 191: 384-390. (Pubitemid 46400700)
79. Rajagopalan S, et al. Platelet activation increases with the severity of peripheral arterial disease: Implications for clinical management. J Vasc Surg 2007; 46: 485-490. (Pubitemid 47371064)
80. Holme PA, et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol 1997; 17: 646-653.. (Pubitemid 27169124)
81. Kroll MH, et al. Platelets and shear stress. Blood 1996; 88: 1525-1541. (Pubitemid 26307046)
82. Nomura S, Komiyama Y. Shear stress and platelet-derived microparticles. Rinsho Byori 1997; 45: 927-933.
83. Cella G, et al. Beta thromboglobulin, platelet production time and platelet function in vascular disease. Br J Haematol 1979; 43: 127-136. (Pubitemid 9251455)
84. Robless PA, et al. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Endovasc Surg 2003; 25: 16-22. (Pubitemid 36527595)
85. Kudoh T, et al. Relation between platelet microaggregates and ankle brachial index in patients with peripheral arterial disease. Thromb Res 2006; 117: 263-269. (Pubitemid 41832297)
86. Ridker PM, et al. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peipheral arterial disease. J Am Med Assoc 2001; 285: 2481-2485. (Pubitemid 32433842)
87. Koksch M, et al. Coagulation, fibrinolysis and platelet P-selectin expression in peripheral vascular disease. Eur J Endovasc Surg 2001; 21: 147-154. (Pubitemid 32243908)
88. Tan KT, et al. Platelet microparticles and soluble P-selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann Med 2005; 37: 61-66. (Pubitemid 40342426)
89. Kamath S, Lip GYH. Fibrinogen: biochemistry, epidemiology and determinants. Q J Med 2003; 96: 711-729. (Pubitemid 37259361)
90. Fibrinogen Studies Collaboration, et al. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality. J Am Med Assoc 2005; 294: 1799-1809.
91. Blann AD, Lip GYH. Virchow's Triad revisited: The importance of soluble coagulation factors, the endothelium, and platelets. Thromb Res 2001; 101: 321-327. (Pubitemid 32206588)
92. Price JF, et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease. Edinburgh Artery Study. Eur Heart J 1999; 20: 344-353. (Pubitemid 29103732)
93. Wattanakit K, et al. Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2005; 180: 389-397. (Pubitemid 41072911)
94. Lip GYH, et al. Baseline abnormalities of endothelial function and thrombogenesis in relation to restenosis in essential hypertension. Blood Coagul Fibrinolysis 2002; 13: 35-41. (Pubitemid 34461699)
95. Vene N, Mavri A, Kosmelj K, et al. High D-dimer-levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulation therapy. Thromb Haemost 2003; 90: 1163-1172. (Pubitemid 38004439)
96. Schillinger M, et al. Fibrinogen predicts restenosis after endovascular treatment of the iliac arteries. Thromb Haemost 2002; 87: 959-965. (Pubitemid 34624876)
97. Roller RE, et al. Changes in the fibrinolytic system with peripheral arterial occlusive disease undergoing percutaneous transluminal angioplasty. Thromb Res 1999; 94: 241-247. (Pubitemid 29238352)
98. Laxdal E, et al. Homocysteine levels, haemostatic risk factors and patency rates after endovascular treatment of the common iliac arteries. Eur J Vasc Endovasc Surg 2006; 31: 244-250. (Pubitemid 43263504)
99. Bartlett JW, et al. Assessing the contribution of fibrinogen in predicting risk of death in mean with paripheral arterial disease. J Thromb Haemost 2009; 7: 270-276.
100. Matsuo T, et al. Fibrin D-dimer in thrombogenic disorders. Semin Thromb Haemost 2000; 26: 101-107. (Pubitemid 30238026)
101. McDermott MM, et al. D-dimer, inflammatory markers and lower extremioty functioning in patients with and without peripheral arterial disease. Circulation 2003; 107: 3191-3198. (Pubitemid 36793090)
102. Danesh J, et al. Fibrin D-dimer and Coronary heart Disease: A prospective study and Meta-analysis. Circulation 2001; 103: 2323-2327. (Pubitemid 32448793)
103. Lassila R, et al. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993; 13: 1738-1742. (Pubitemid 23360559)
104. Musicant SE, et al. Prospective evaluation of the relationship between C-reactive protein, d-dimer and progression of peripheral arterial disease. J Vasc Surg 2006; 43: 772-780.
105. Mota AP, et al. Hypercoagulability markers in patients with peripheral arterial disease: association to ankle-brachial index. Angiology Nov 2008; prepub online.
106. Ridker PM, et al. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236-2240. (Pubitemid 24354307)
107. Reiner AP, et al. Haemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001; 85: 584-595. (Pubitemid 32293691)
108. Philipp CS, et al. Association of haemostatic factors with peripheral vascular disease. Am Heart J 1997; 134: 978-984. (Pubitemid 27523006)
109. Sobel BE. Increased PAI-1 and vasculopathy: a reconsilable paradox. Circulation 1999; 99: 2496-2498.
110. Loskutoff DJ, et al. Regulation of PAI-1 gene expression in vivo. Thromb Haemost 1993; 70: 135-137. (Pubitemid 23225465)
111. Felmelden DC, Lip GYH. Endothelial function and its assessment. Expert Opin Investig Drugs 2005; 14: 1319-1336. (Pubitemid 41613362)
112. Cessari M, Rossi GP. Plasminogen activator inhibitor type 1 in ischaemic cardiomyopathy. Arterioscler Thromb Vasc Biol 1999; 19: 1378-1386. (Pubitemid 29263006)
113. Devaraj S, et al. C-Reactive protein increases Plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398-404.
114. Sawa H, et al. Increased intramural expression of Plasminogen activator inhibitor type 1 after balloon injury: A potential progenitor of restenosis. J Am Coll Cardiol 1994; 24: 1742-1748. (Pubitemid 24369201)
115. Kronenberg F, et al. Role of Lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the Bruneck Study. Circulation 1999; 100: 1154-1160. (Pubitemid 29426589)
116. Loscalzo J, et al. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10: 240-245. (Pubitemid 20103586)
117. Paraskevas KI, et al. The role of fibrinogen and fibrinolysis in peripheral arterial disease. Throb Res 2008; 122: 1-12 (Pubitemid 351618332)
118. Palabrica TM, et al. Anti-fibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue Plasminogen activator-mediated thrombolysis. Nat Med 1995; 1: 256-259.
119. Cheng SW, et al. Lipoprotein(a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc Surg 1997; 14: 17-23. (Pubitemid 27380176)
120. Tseng CH. Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan. Diabetes Care 2004; 27: 517-521. (Pubitemid 38174081)
121. Libby P, et al. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143. (Pubitemid 34212626)
122. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003; 26: 3333-3341. (Pubitemid 37466898)
123. Vinik AI, et al. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-1485. (Pubitemid 33716440)
124. Tzoulaki I, et al. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005; 112: 976-983. (Pubitemid 41170265)
125. Allison MA, et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2006; 48: 1190-1197. (Pubitemid 44345134)
126. Armitage JD, et al. The role of endothelial cell reactive antibodies in peripheral arterial disease. Eur J Endovasc Surg 2006; 31: 170-175. (Pubitemid 43078945)
127. Riba R, et al. Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis 2004; 175: 69-75. (Pubitemid 38746911)
128. Hogh AL, et al. C-reactive protein predicts future arterial and cardiovascular events in patients with symptomatic peripheral arterial disease. Vasc Endovascular Surg 2008; 42: 341-347.
129. Wall RT, et al. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980; 18: 113-121. (Pubitemid 10109903)
130. Silverman MD, et al. Homocysteine unregulates vascular cell adhesion molecule-1 expression in cultures aortic endothelial cells and enhances monocyte adhesion. Arterioscler Thromb Vasc Biol 2002; 22: 587-592. (Pubitemid 34408738)
131. Moghadasian MH, et al. Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch Intern Med 1997; 157: 2299-2308.
132. Welch GN, Loscolzo J. Homocysteine and atherosthrombosis. N Eng J Med 1998; 338: 1042-1045.
133. Boushey CJ, et al. A quatitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995; 274: 1049-1057.
134. Taylor LM Jr. Elevated plasma homocysteine as a risk factor for peripheral arterial disease: what is the evidence? Semin Vasc Surg 2003; 16: 215-222.
135. st century. Impact of hyperhomocysteinemia on patency and amputation-free survival after intervention for crtitical limb ischaemia. J Endovasc Ther 2008; 15: 399-407.
136. Lowe GDO, et al. Blood viscosity, fibrinogen, and activation of coagulation and leokocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 1993; 87: 1915-1920. (Pubitemid 23165634)
137. Lee AJ, et al. Blood viscosity and elevated carotid intima-media thickness in men and women: The Edinburgh Artery Study. Circulation 1998; 97: 1467-1473. (Pubitemid 28191302)
138. Smith FB, et al. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998; 100: 758-763. (Pubitemid 28126111)
139. Van Der Loo B, et al. Carotid intima-media thickness, carotid wall shear stress and restenosis after femoro-popliteal percutaneous transluminal angioplasty (PTA). Eur J Vasc Surg 2005; 30: 469-474. (Pubitemid 41472412)
140. Gori T, et al. Endothelium and haemorheology. Ann Ist Sanita 2007; 43: 124-129.
141. Shaaban AM, Duerinckx AJ. Wall shear stress and early atherosclerosis: A review. AJR 2000; 174: 1657-1665. (Pubitemid 30346735)
142. Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of atherosclerosis. Lab Invest 2005; 85: 9-23. (Pubitemid 40128037)
143. Niwa K, et al. The effects of a shear flow on the uptake of LDL and acetylated LDL by an EC monoculture and an EC-SMC coculture. Ann Biomed Eng 2004; 32: 537-543.
144. Chiu JJ, et al. Shear stress increases ICAM-1 and decreases VCAM-1 and E-selectin expressions induced by tumour necrosis factor-alpha in endothelial cells. Arteriosclerosis Thrombosis Vasc Biol 2004; 24: 73-79. (Pubitemid 38082414)
145. Walpola PL, et al. Expression on ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress. Arteriosclerosis Thrombosis Vasc Biol 1995; 15: 2-10.
146. Spring S, et al. Decreased wall shear stress in the common carotid artery of patients with peripheral arterial disease or abdominal aortic aneurysm: Relation to blood rheology, vascular risk factors, and intimamedial thickness. J Vasc Surg 2006; 43: 56-63. (Pubitemid 43083508)
147. Irace C, et al. Wall shear stress is associated with intima-media thickness and carotid atherosclerosis in subjects at low coronary heart disease risk. Stroke 2004; 35: 464-468. (Pubitemid 38174431)
148. Asakura T, Karino T. Flow patterns and spatial distribution of atherosclerotic lesions in human coronary arteries. Circ Res 1990; 66: 1045-1066. (Pubitemid 20126435)
149. Gnasso A, et al. In vivo association between low wall shear stress and plaque in subjects with asymmetrical carotid atherosclerosis. Stroke 1997; 28: 993-998.
150. Zarins CK, et al. Carotid bifurcation atherosclerosis; quantitative correlation of plaque localisation with flow velocity profiles and wall shear stress. Circ Res 1983; 53: 502-514. (Pubitemid 14231103)
151. Khaleghi M, et al. Haemostatic markers are associated with measures of vascular disease in adults with hypertension. J Hum Hypertens 2009; 1: 1-8.
152. Gosk-Bierska I, et al. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischaemia: preliminary study. Int Angiol 2008; 27: 296-301.
153. McDermott MM, et al. Circulating blood markers and functional impairment in peripheral arterial disease. J Am Geriatr Soc 2008; 56: 1504-1510.
154. Vidula H, et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: A cohort study. Ann Intern Med 2008; 148: 85-93. (Pubitemid 351651551)
155. Sodhi HS, et al. Prevalence of peripheral arterial disease by ankle-brachial index and its correlation with carotid intimal thickness and coronary risk factors in Nepalese population over the age of forty years. Kathmandu Univ Med J. 2007; 1: 12-15.
156. Cleanthis M, et al. Platelet monocyte aggregates and monocyte chemoattractant protein-1 are not limited by aspirin in critical limb ischaemia. Eur J Endovasc Surg 2007; 33: 725-730. (Pubitemid 46672814)
157. Brevetti G, et al. Metabolic syndrome in peripheral arterial disease: relationship with severity of peripheral circulatory insufficiency, inflammatory status, and cardiovascular comorbidity. J Vasc Surg. 2006; 44: 101-107. (Pubitemid 43975268)
158. Unlu Y, et al. Comparison of levels of inflammatory markers and haemostatic factors in the patients with and without peripheral arterial disease. Thromb Res 2006; 117: 357-364. (Pubitemid 43197485)
159. Sofi F, et al. Thrombophilic risk factors for symptomatic peripheral arterial disease. J Vasc Surg 2005; 41: 255-260. (Pubitemid 40342476)
160. Wildman RP, et al. Relation of inflammation to peripheral arterial disease in the National Health and Nutrition Examination Survey, 1999-2002. Am J Cardiol 2005; 96: 1579-1583.
161. Urge J, et al. Pharmacotherapeutical approaches to decreasing haematocrit and increasing claudication distance in diabetic patients with peripheral vascular disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005; 149: 267-270.
162. Parsson H, et al. Activation of coagulation and fibrinolytic systems with CLI is not normalised after surgical revascularisation. Eur J Endovasc Surg 2004; 27: 186-192. (Pubitemid 38111687)
163. Koscielny J, et al. Blood fluidity, fibrinogen, and cardiovascular risk factors of occlusive arterial disease: Results of the Aachen study. Clin Haemorheol Microcirc 2004; 31: 185-195. (Pubitemid 39362719)